NDAINTRAMUSCULARSOLUTION
Approved
Apr 1983
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1m ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Pralidoxime chloride is an acetylcholinesterase reactivator administered via autoinjector for rapid intramuscular delivery. It is indicated for treatment of organophosphate poisoning and nerve agent exposure. The drug works by reactivating inhibited acetylcholinesterase, restoring normal neurotransmission.
LOE Approaching
Product lifecycle is approaching loss of exclusivity with limited commercial momentum, indicating small team focus on generic transition planning and niche market defense.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This product offers limited career growth opportunities given its mature status and approaching LOE, with focus primarily on defensive commercial strategies and regulatory compliance. Positions available are typically maintenance-oriented rather than growth-driven, making it less attractive for career advancement.
Brand ManagerProduct Manager
Worked on PRALIDOXIME CHLORIDE (AUTOINJECTOR) at CooperSurgical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.